14 Citations (Scopus)

Abstract

The discovery of small regulatory noncoding RNAs revolutionized our thinking on gene regulation. The class of microRNAs (miRs), a group of small noncoding RNAs (20-22 nt in length) that bind imperfectly to the 3'-untranslated region of target mRNA, has been insistently implicated in several pathological conditions including cancer. Indeed, major hallmarks of cancer, such as cell differentiation, cell proliferation, cell cycle, cell survival, and cell invasion, has been described as being regulated by miRs. Recent studies have also implicated miRs in cancer drug resistance. Regardless of the several studies done until now, drug resistance still is a burden for cancer therapy and patients' outcome, often resulting in more aggressive tumors that tend to metastasize to distant organs. Hence, with this review, we aim to summarize the miRs that influence molecular pathways that are involved in cancer drug resistance, such as drug metabolism, drug influx/efflux, DNA damage response (DDR), epithelial-to-mesenchymal transition (EMT), and cancer stem cells.

Original languageEnglish
Pages (from-to)137-62
Number of pages26
JournalMethods In Molecular Biology (Clifton, N.J.)
Volume1395
DOIs
Publication statusPublished - 2016

Fingerprint

MicroRNAs
Drug Resistance
Small Untranslated RNA
Neoplasms
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
3' Untranslated Regions
Mesenchymal Stromal Cells
Pharmaceutical Preparations
DNA Damage
Cell Differentiation
Cell Survival
Cell Cycle
Cell Proliferation
Messenger RNA
Genes

Keywords

  • MicroRNA
  • Drug resistance
  • Noncoding RNAs
  • Cancer

Cite this

@article{a8856589d38246418064e858d423d9a2,
title = "MicroRNAs and Cancer Drug Resistance",
abstract = "The discovery of small regulatory noncoding RNAs revolutionized our thinking on gene regulation. The class of microRNAs (miRs), a group of small noncoding RNAs (20-22 nt in length) that bind imperfectly to the 3'-untranslated region of target mRNA, has been insistently implicated in several pathological conditions including cancer. Indeed, major hallmarks of cancer, such as cell differentiation, cell proliferation, cell cycle, cell survival, and cell invasion, has been described as being regulated by miRs. Recent studies have also implicated miRs in cancer drug resistance. Regardless of the several studies done until now, drug resistance still is a burden for cancer therapy and patients' outcome, often resulting in more aggressive tumors that tend to metastasize to distant organs. Hence, with this review, we aim to summarize the miRs that influence molecular pathways that are involved in cancer drug resistance, such as drug metabolism, drug influx/efflux, DNA damage response (DDR), epithelial-to-mesenchymal transition (EMT), and cancer stem cells.",
keywords = "MicroRNA, Drug resistance, Noncoding RNAs, Cancer",
author = "Gomes, {Bruno Costa} and Jos{\'e} Rueff and A.S. Rodrigues",
note = "PMID:26910073",
year = "2016",
doi = "10.1007/978-1-4939-3347-1_9",
language = "English",
volume = "1395",
pages = "137--62",
journal = "Methods In Molecular Biology (Clifton, N.J.)",
issn = "1064-3745",
publisher = "Humana Press",

}

MicroRNAs and Cancer Drug Resistance. / Gomes, Bruno Costa ; Rueff, José; Rodrigues, A.S.

In: Methods In Molecular Biology (Clifton, N.J.), Vol. 1395, 2016, p. 137-62.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MicroRNAs and Cancer Drug Resistance

AU - Gomes, Bruno Costa

AU - Rueff, José

AU - Rodrigues, A.S.

N1 - PMID:26910073

PY - 2016

Y1 - 2016

N2 - The discovery of small regulatory noncoding RNAs revolutionized our thinking on gene regulation. The class of microRNAs (miRs), a group of small noncoding RNAs (20-22 nt in length) that bind imperfectly to the 3'-untranslated region of target mRNA, has been insistently implicated in several pathological conditions including cancer. Indeed, major hallmarks of cancer, such as cell differentiation, cell proliferation, cell cycle, cell survival, and cell invasion, has been described as being regulated by miRs. Recent studies have also implicated miRs in cancer drug resistance. Regardless of the several studies done until now, drug resistance still is a burden for cancer therapy and patients' outcome, often resulting in more aggressive tumors that tend to metastasize to distant organs. Hence, with this review, we aim to summarize the miRs that influence molecular pathways that are involved in cancer drug resistance, such as drug metabolism, drug influx/efflux, DNA damage response (DDR), epithelial-to-mesenchymal transition (EMT), and cancer stem cells.

AB - The discovery of small regulatory noncoding RNAs revolutionized our thinking on gene regulation. The class of microRNAs (miRs), a group of small noncoding RNAs (20-22 nt in length) that bind imperfectly to the 3'-untranslated region of target mRNA, has been insistently implicated in several pathological conditions including cancer. Indeed, major hallmarks of cancer, such as cell differentiation, cell proliferation, cell cycle, cell survival, and cell invasion, has been described as being regulated by miRs. Recent studies have also implicated miRs in cancer drug resistance. Regardless of the several studies done until now, drug resistance still is a burden for cancer therapy and patients' outcome, often resulting in more aggressive tumors that tend to metastasize to distant organs. Hence, with this review, we aim to summarize the miRs that influence molecular pathways that are involved in cancer drug resistance, such as drug metabolism, drug influx/efflux, DNA damage response (DDR), epithelial-to-mesenchymal transition (EMT), and cancer stem cells.

KW - MicroRNA

KW - Drug resistance

KW - Noncoding RNAs

KW - Cancer

U2 - 10.1007/978-1-4939-3347-1_9

DO - 10.1007/978-1-4939-3347-1_9

M3 - Article

VL - 1395

SP - 137

EP - 162

JO - Methods In Molecular Biology (Clifton, N.J.)

JF - Methods In Molecular Biology (Clifton, N.J.)

SN - 1064-3745

ER -